Product category:
Cell/tissue handling and counting
News Release from: Microbix Biosystems
Edited by the Laboratorytalk Editorial
Team on 15 February 2007
Microbix announces changes to board of
directors
Vaughn Embro-Pantalony has been appointed to the board of directors, replacing James A Long who has assumed his duties as chief financial officer, and has resigned as a director
"Jim Long has played an important role and assumed many duties as a director since the inception of the company and I am delighted to have him on the executive team and bringing his years of experience in financial management to his new key role in the development of our business," said William Gastle, chief executive officer "Vaughn Embro-Pantalony is a familiar person in the company having worked with Microbix in business development and licensing
This article was originally published on Laboratorytalk on 20 Mar 2003 at 8.00am (UK)
Related stories
Double anniversary at Focus
Supplier of one quarter of the world's haematology analysers celebrates its twentieth birthday, while its parent company celebrates its fiftieth
Merger of HTP operations
"With a combined instrumentation and biochemistry team we can respond faster and more flexibly to the assaying demands of current and future customers"
"He is an experienced finance executive having worked at Novopharm, Bayer Canada, and Zeneca Pharma.
"His extensive experience in financial governance, external reporting, audit, tax, financing, product licensing and mergers and acquisitions will strengthen and broaden the knowledge base already in place at Microbix".
Embro-Pantalony has a BA in economics from Wilfred Laurier University, an MBA from the University of Windsor and is a certified management accountant.
He has also completed the executive programme at Princeton University.
His consulting practice, StratPath, specialises in providing financial solutions to life science companies.
Gastle went on to say: "Vaughn's appointment is an ongoing part of the reorganization of the board and executive team and these changes come at the right time for us to move forward in building our business on the most significant scientific opportunities created by the company".
Microbix specialises in developing proprietary biological technologies and commercialising them through global partners.
Its products include biotherapeutic drugs, vaccines, and infectious disease diagnostics.
Established in 1988, the company is headquartered in Toronto.
• Microbix Biosystems: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
